Citizens JMP analyst David Turkaly lowered the firm’s price target on OrthoPediatrics (KIDS) to $25 from $35 and keeps an Outperform rating on the shares. OrthoPediatrics’ preliminary Q3 revenue was 4% below consensus, but Citizens believes that the core business fundamentals, the stock’s valuation, management’s conservative outlook, and the reiterated forward cash flow metrics still support a bullish outlook long-term, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics price target lowered to $20 from $32 at Stifel
- OrthoPediatrics price target lowered to $22 from $30 at Piper Sandler
- OrthoPediatrics: Strong Growth Prospects and Acquisition Potential Justify Buy Rating
- Closing Bell Movers: Levi Strauss down 8% after results
- OrthoPediatrics reports preliminary Q3 revenue $61.2M, consensus $63.63M